RAVENSBURG, Germany--(BUSINESS WIRE)--Vetter, a leading global contract development and manufacturing organization (CDMO) for the development, commercial manufacturing and final packaging of aseptically prefilled drug-delivery systems, today announced the construction of a new building at a ground breaking ceremony held at its Ravensburg Schuetzenstrasse site. Scheduled for completion in the first quarter of 2018, the building is planned to begin operations in early 2019. Expected to cost approximately 70 million euro ($79 million), it is part of the total investment strategy announced by the company in September 2015, and will constitute an important element in the overall Schuetzenstrasse facility rebuilding concept for modernization and expansion.
Upon completion, the seven story building will cover a total of 8,000 sq. meters (86,000 sq. ft),
and include in its core a cleanroom with supportive media systems. Additionally, it will contain the site’s central material preparation; office space for the production staff as well as a staff canteen with roof garden. The applied technology of the cleanroom will be dedicated to the filling of bulk syringes and designed to be compatible for the filling of sensitive drugs such as biologics and opthalmics. Syringes prepared in the bulk process offer a number of customization options that are tailored to substance and primary packaging material components, and offer customizable low silicone levels and thus, process flexibility. Another central technological element of the cleanroom will be the implementation of an improved restricted access barrier system (RABS) concept to combine the advantages of isolator and RABS technology. The core of this innovative approach is a uniquely fast, by today’s standards, 3-hour cycle and fully automated decontamination of the cleanroom using hydrogen peroxide (H2O2).
“This addition to our Schuetzenstrasse site is an exciting chapter in our company’s history and will again support Vetter’s target to offer its customers the adequate high manufacturing quality for their high value drugs”, said Vetter Managing Director Thomas Otto. “Attaining this high level of quality is of particular significance to Vetter as it represents one of our core customer relations value propositions."
About Vetter
Vetter is a global leader in the fill and finish of aseptically prefilled syringe systems, cartridges and vials. Headquartered in Ravensburg, Germany, with production facilities in Germany and the United States, the contract development and manufacturing organization (CDMO) is an innovative solution provider serving the top 10 (bio-)pharmaceutical companies, as well as small and midsize companies. Its portfolio spans state-of-the-art manufacturing from early clinical development through commercial filling and final packaging of parenteral drugs. The company’s extensive experience covers a broad range of complex compounds including monoclonal antibodies, peptides and interferons. Vetter supports its customers every step of the way, guiding their products through development, regulatory approval, launch and lifecycle management. Known for quality, the company of approximately 3,600 employees offers a foundation of experience spanning more than 35 years, including dozens of customer product approvals for novel (bio-)pharmaceutical compounds. The CDMO is also committed to patient safety and compliance with user friendly solutions such as Vetter-Ject®, as well as its dual-chamber syringe Vetter Lyo-Ject® and cartridge system V-LK®. Vetter’s branch office in Singapore and its subsidiary in Tokyo, Japan, increase the presence of the company and the awareness of its service portfolio in the Asian healthcare market. Visit www.vetter-pharma.com.
